Ranbaxy opens new plant in Morocco

12 March 2012

Ranbaxy Morocco, a unit of India’s largest drugmaker Ranbaxy Laboratories (AB: BO), which is majority owned by Japan-based Daiichi Sankyo, said yesterday that it has opened its new manufacturing facility at Casablanca, Morocco, paving the way for a direct business presence in North Africa.

With the successful audit of the facility by the Moroccan Health Authorities, Ranbaxy Morocco is now authorized to commence manufacturing of its products at its Casablanca facility. The achievement of this milestone positions Ranbaxy to access a $1 billion pharmaceutical market in Morocco.

Commenting on the inauguration of the manufacturing facility at Morocco, Mahendra Bhardwaj, head, Africa, Ranbaxy, said: "Ranbaxy has a significant presence in Africa with its own ground operations in key markets. Morocco is one of the important markets and this manufacturing facility further reinforces our commitment to the people of Morocco and the African continent."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK